AllAnalyst Report
Morningstar•December 22, 2020
Morningstar•December 22, 2020Perrigo Company plc: Perrigo Reports Another Quarter With Numerous Puts and Takes, Irish Tax Woes Remain an Overhang
Summary
Perrigo is the leading provider of over-the-counter generic drugs with over 100 global locations. The company was formed in 1887 as a packager of home remedies and has grown with the migration of prescriptions switching to OTC and later with strategic acquisitions. The company has a portfolio of more than 3,000 product formulations and 14,000 stock-keeping units. Most of its manufacturing and customer base reside in North America. With the most recent management change, the company announced a narrower focu
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeActions
Download Full ReportRelated Reports
- Analyst Report: Pentair plcApr 24, 2024 •
PNR
- Analyst Report: Abbott LaboratoriesApr 23, 2024 •
ABT
- Market Update: ABT, ERIC, IVZApr 23, 2024 •
ABT, ERIC, IVZ
- Analyst Report: The Procter & Gamble CompanyApr 22, 2024 •
PG
- Technical Assessment: Neutral in the Intermediate-TermApr 22, 2024 •
CVX, PFE
Analyst Profile
Soo Romanoff
Equity AnalystTancrede Fulop, CFA, is an equity analyst for Morningstar Holland BV, a wholly owned subsidiary of Morningstar, Inc. He covers European utilities.Before joining Morningstar in early 2017, Fulop worked for Schlumberger Business Consulting as a financial and economist analyst. Previously, he was a senior research associate covering European utilities for Raymond James from 2011 to 2015.Fulop holds a master’s degree in finance from the University Paris II Pantheon-Assas. He also holds the Chartered Financial Analyst® designation.